Information Provided By:
Fly News Breaks for August 6, 2019
BCRX
Aug 6, 2019 | 11:30 EDT
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $10 price target on BioCryst as he believes BCX7353 is a "viable product," while the rest of the pipeline is receiving little to no value. Having less than 12 months of cash is "clearly weighing" on the shares as the company heads toward a product launch in HAE prophylaxis, he acknowledges, but adds that he believes the company has several creative options at its disposal in addition to a potential strategic deal for ex-U.S. rights.
News For BCRX From the Last 2 Days
There are no results for your query BCRX